Advaxis, Amgen strike $540M preclinical-stage immunotherapy alliance; $40M cash up front
Global rights to Advaxis Inc.’s preclinical cancer immunotherapy, ADXS-NEO, are going to Amgen Inc. for a combined pledge of up to $540 million, giving Advaxis new cash to fuel its FDA fast-tracked phase III cervical cancer treatment, AXAL, while feeding Amgen’s ongoing interest in cancer vaccines, a pursuit that led to approval of the first FDA-approved oncolytic virus therapy, Imlygic (talimogene laherparepvec), last October.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST